Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for type 2 diabetes and obesity, have been at the forefront of repurposing efforts for neurodegenerative diseases. These drugs, including exenatide and semaglutide, have shown promising neuroprotective effects in preclinical studies and smaller clinical trials. However, the first phase 3 trial testing exenatide in Parkinson’s disease has delivered disappointing results, failing to demonstrate clinical benefit. Published in The Lancet, the study by Vijiaratnam et al. represents a crucial moment for GLP-1 receptor agonist research in neurodegeneration.
Why GLP-1 Agonists Were Promising for Parkinson’s?
The rationale behind using GLP-1 receptor agonists in Parkinson’s disease was built on multiple lines of evidence:
1. Preclinical Success – Studies in rodent models of dopaminergic neurodegeneration showed that peripherally administered exenatide reduced neuronal loss and improved motor function.
2. Epidemiological Evidence – Large population-based studies suggested that patients with type 2 diabetes who were treated with GLP-1 receptor agonists had a lower risk of developing Parkinson’s.
3. Phase 2 Trial Signals – A small, single-centre phase 2 trial in Parkinson’s patients suggested that exenatide treatment improved motor function that persisted even after a drug washout period, hinting at a disease-modifying effect.
These findings set the stage for a more significant, more definitive phase 3 trial to determine whether exenatide could truly alter the course of Parkinson’s disease.
The Phase 3 Trial: Design and Key Findings
The phase 3 study was a multi-centre, randomised, placebo-controlled trial conducted across six sites in the UK. A total of 194 participants with Parkinson’s disease were enrolled, all of whom were already receiving standard dopaminergic therapy. Notably, individuals with type 2 diabetes were excluded to avoid confounding effects.
• Primary Outcome: The study assessed motor symptoms using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS Part III) in the OFF-medication state after 96 weeks of treatment.
• Results: No statistically significant difference was found between the exenatide and placebo groups (mean score of 37.6 for exenatide vs. 36.6 for placebo).
• Secondary Outcomes: Measures of non-motor symptoms, quality of life, and imaging markers of dopaminergic function also showed no significant benefit.
• Dopamine Transporter Imaging (DaT-SPECT): This exploratory biomarker outcome found no meaningful difference in the rate of dopaminergic decline between treatment groups.
In short, the trial failed to show that exenatide had any disease-modifying effects in Parkinson’s disease.
What Went Wrong?
The disappointing results raise several important questions:
1. Was the Drug Reaching the Brain in High Enough Concentrations?
• Previous studies have shown that exenatide has a low cerebrospinal fluid (CSF)-to-blood ratio, meaning relatively little of the drug crosses the blood-brain barrier.
• The phase 3 trial found lower CSF exenatide levels than expected, suggesting inadequate central nervous system exposure may have contributed to the lack of efficacy.
2. Trial Design Issues
• Participants were already on dopaminergic medications, and the primary outcome relied on OFF-medication motor scores, which are highly variable.
• Chronic dopaminergic therapy might have influenced brain signalling in ways that masked potential neuroprotective effects.
3. The “Lessebo Effect”
• Weight loss, a common side effect of exenatide, was less pronounced in this trial than in previous studies.
• Patients receiving the active drug may have suspected they were in the placebo group, affecting subjective measures of motor function.
4. Is GLP-1 Agonism Insufficient as a Standalone Therapy?
• GLP-1 receptor agonists have anti-inflammatory and neuroprotective properties, but they may not be enough on their own to significantly slow Parkinson’s progression.
• Combination therapies targeting multiple pathways (e.g., inflammation, mitochondrial dysfunction, and alpha-synuclein aggregation) may be necessary.
What’s Next for GLP-1 Agonists in Neurodegeneration?
Despite this setback, GLP-1 receptor agonists are still being explored for other neurodegenerative conditions.
• Alzheimer’s Disease:
• A large phase 3 trial is currently underway testing semaglutide in early-stage Alzheimer’s patients.
• Unlike Parkinson’s, Alzheimer’s pathology may be more influenced by systemic metabolic factors like insulin resistance, making GLP-1 receptor agonists a more viable therapeutic option.
• Parkinson’s Disease – Future Directions:
• Higher CNS-penetrant GLP-1 receptor agonists may be needed to achieve better outcomes.
• Future trials could focus on earlier disease stages or patients with specific metabolic profiles that make them more likely to respond to treatment.
• Other Inflammatory and Metabolic Disorders:
• The link between neurodegeneration and metabolic dysfunction is well established, meaning GLP-1 receptor agonists may still play a role in broader neuroprotection strategies.
Conclusion
The phase 3 trial of exenatide for Parkinson’s disease failed to meet its primary and secondary endpoints, marking a significant disappointment for the field. However, rather than abandoning GLP-1 receptor agonists entirely, these findings highlight the importance of refining trial design, optimizing drug delivery, and identifying the right patient populations for future studies.
As researchers continue to explore the complex relationship between metabolic dysfunction and neurodegeneration, GLP-1 receptor agonists remain an area of active investigation. While exenatide may not be the breakthrough many had hoped for, lessons from this trial will help shape the future of neurodegenerative disease therapeutics.
Discover more from Neurospan
Subscribe to get the latest posts sent to your email.
